Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: bimatoprost 0.01%

Study type: Observational

Funder types: Industry

Identifiers

NCT01628588

MAF/AGN/OPH/GLA/026

Details and patient eligibility

About

This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Enrollment: 854 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary open angle glaucoma or ocular hypertension
• Prescribed Lumigan®

Exclusion criteria

• None

Trial design

854 participants in 1 patient group

POAG or OHT

Description:

Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry

Treatment:

Drug: bimatoprost 0.01%